The recent failures of potential disease-modifying drugs for Alzheimer's disease (AD) may
reflect the fact that the enrolled participants in clinical trials are already too advanced to …

The introduction of in vivo imaging of Aβ-amyloid (Αβ) pathology more than a decade ago,
transformed the assessment of Alzheimer disease (AD) allowing the evaluation of Aβ …

Importance Midlife vascular risk factors have been associated with late-life dementia.
Whether these risk factors directly contribute to brain amyloid deposition is less well …

Positron emission tomography (PET) allows detecting molecular brain changes in vivo.
However, the accuracy of PET is limited by partial volume effects (PVE) that affects …

See Vandenberghe and Schaeverbeke (doi: 10.1093/awx065) for a scientific commentary
on this article. A long-term goal of our field is to determine the sequence of pathological …

In Alzheimer's disease (AD), insoluble and fibrillary amyloid-β (Aβ) peptide accumulates in
plaques. However, soluble Aβ oligomers are most potent in creating synaptic dysfunction …

The past decade has seen tremendous efforts in biomarker discovery and validation for
neurodegenerative diseases. The source and type of biomarkers has continued to grow for …

Background 18 F‐florbetapir uptake by brain tissue measured by positron emission
tomography (PET) is accepted by regulatory agencies like the Food and Drug Administration …

Alzheimer disease (AD) was originally conceived as a rare disease that caused presenile
dementia but has come to be understood as the most prevalent cause of dementia at any …

Positron emission tomography (PET) imaging agents that detect amyloid plaques containing
amyloid beta (Aβ) peptide aggregates in the brain of Alzheimer's disease (AD) patients have …